Myeloproliferative Neoplasms: Biology and Therapy (Contemporary Hematology)

This succinct resource provides an ideal balance of the biology and practical therapeutic strategies for classic and non-classic BCR-ABL-negative myeloproliferative neoplasms. Utilizing current World Health Organization nomenclature, classification, and diagnostic criteria, international experts have assembled to convey the most up-to-date knowledge in this rapidly evolving field. The opening chapters cover the diagnosis and classification, genetics, cytogenetic findings, and prognostic factors of MPNs. Further chapters explore therapies specific to the different disease entities, including polycythemia vera, essential thrombocytopenia, myelofibrosis, and eosinophilic disorders, and mastocytosis. Unique areas of discussion include JAK2 inhibitor therapy, hematopoietic stem cell transplantation, and blastic transformation. A valuable reference for practicing hematologists, this forefront book enriches our understanding of recent discoveries and their impact on conventional and investigational treatments. This succinct resource features the most up-to-date knowledge on myeloproliferative neoplasms, including discoveries in JAK2 and MPL mutations, groundbreaking knowledge of the FIP1L1-PDGFRA mutation, new nomenclature and classification, revised WHO-based diagnostic criteria, novel molecular abnormalities, and therapies. International experts provide an ideal balance of new discoveries in biology and practical therapeutic strategies for these diseases. The authors detail new understanding of genetic mutations and the impact on both the pathophysiologic and clinical contexts of myeloproliferative neoplasms. Diseases covered include essential thrombocythemia, primary and secondary myelofibrosis, hypereosinophic syndrome, chronic eosinophilic leukemia, and systemic mastocytosis. Attention is given to bone marrow findings, revised classification and WHO-based diagnostic criteria, prognostic factors, and treatment options. The full range of therapies is explored from conventional to investigational and anti-JAK2 small molecule drugs to transplant Front Matter....Pages i-x Diagnosis and Classification of the BCR-ABL1-Negative Myeloproliferative Neoplasms....Pages 1-37 Genetics of the Myeloproliferative Neoplasms....Pages 39-68 Cytogenetic Findings in Classical MPNs....Pages 69-83 Prognostic Factors in Classic Myeloproliferative Neoplasms....Pages 85-96 Therapy of Polycythemia Vera and Essential Thrombocythemia....Pages 97-115 Conventional and Investigational Therapy for Primary Myelofibrosis....Pages 117-138 Hematopoietic Cell Transplantation for Myelofibrosis....Pages 139-150 JAK2 Inhibitors for Therapy of Myeloproliferative Neoplasms....Pages 151-167 Blastic Transformation of Classic Myeloproliferative Neoplasms....Pages 169-180 Eosinophilic Disorders: Differential Diagnosis and Management....Pages 181-203 Pathogenesis, Diagnosis, Classification, and Management of Systemic Mastocytosis....Pages 205-221 Back Matter....Pages 223-228